Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;36(4):197-202.

Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer

Enock Anassi, Uche Anadu Ndefo

Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer

Enock Anassi et al. P T. 2011 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Two signals are required for T-cell activation. APC = antigen-presenting cell; MHC = major histocompatibility complex.
Figure 2
Figure 2
Activity of dendritic cells in fighting cancer. (From the National Cancer Institute.11)
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249. - PubMed
    1. Fauci AS, Kasper DL, Braunwald E, et al., editors. Harrison’s Principles of Internal Medicine. 17th ed. New York: McGraw-Hill; 2008. pp. 594–600.
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512. - PubMed
    1. Ross RW, Kantoff PW. Hormone-refractory prostate cancer: Choosing the appropriate treatment option. Oncology (Williston Park) 2007;21:185–193. - PubMed
    1. Newling DW, Dennis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer: Analysis of the criteria for evaluation used in the European Organization for Research and Treatment of Cancer. Genitourinary Group Study, 30853. Cancer (Phila) 1993;72:3793–3798. - PubMed

LinkOut - more resources